Sex-related differences in relations of uric acid to left ventricular hypertrophy and remodeling in Japanese hypertensive patients

Hypertension Research

Volumn 28, Issue 2, 2005, Pages 133-139

  Kurata, Akira ^a   Shigematsu, Yuji ^a   Higaki, Jitsuo ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Concentric hypertrophy; Essential hypertension; Left ventricular mass; Serum uric acid

Indexed keywords

CREATININE; URIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; HYPERURICEMIA; JAPAN; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; JAPAN; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; URIC ACID; VENTRICULAR REMODELING;

EID: 18644368836     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.28.133     Document Type: Article

References (38)

1. Gertler MM, Garn SM, Levine SA: Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951; 34: 1421-1431.
2. Brand FN, McGee DL, Kannel WB, Stokes J, Castelli WP: Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol 1985; 121: 11-18.
3. Abbott RD, Brand FN, Kannel WB, Castelli WP: Gout and coronary disease: the Framingham Study. J Clin Epidemiol 1988; 41: 237-242.
4. Levine W, Dyer AR, Shekelle RB, Shekelle RB, Schoenberger JA, Stamler J: Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industory. J Clin Epidemiol 1989; 42: 257-267.
5. Nakanishi N, Tatara K, Nakamura K, Suzuki K: Risk factors for the incidence of hyperuricemia: a 6-year longitudinal study of middle-aged Japanese men. Int J Epidemiol 1999; 28: 888-893.
6. Franse LV, Pahor M, DiBari M, et al: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149-1554.
7. Inoue T, Matsuoka M, Nagahama K, et al: Cardiovascular risk factors associated with pulse pressure in screened cohort in Okinawa, Japan. Hypertens Res 2003; 26: 153-158.
8. Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S: Hyperuicemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 227-233.
9. Casale PN, Devereux RB, Milner M, et al: Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-178.
10. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
11. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. Ann Intern Med 1989; 110: 101-107.
12. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
13. Shigematsu Y, Hamada M, Mukai M, Matsuoka H, Sumimoto T, Hiwada K: Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension. J Hypertens 1995; 13: 155-160.
14. Shigematsu Y, Hamada M, Ohtsuka T, et al: Left ventricular geometry as an independent predictor for extracardiac target organ damage in essential hypertension. Am J Hypertens 1998; 11: 1171-1177.
15. Cuspidi C, Meani S, Salerno M, et al: Cardiovascular target organ damage in essential hypertensive with or without reproducible nocturnal fall in blood pressure. J Hypertens 2004; 22: 273-280.
16. Japanese Society of Hypertension Guideline Subcommittee for the Management of Hypertension: Guideline for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634.
17. Shigematsu Y, Hamada M, Okayama H, et al: Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 1997; 29: 723-727.
18. Sahn DJ, DeMaria A, Kisslo J, Weyman A: The Committee on M-Mode Standardization of the American Society of Echocardiography: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
19. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618.
20. Dubin J, Wallerson DC, Cody RJ, Devereux RB: Comparative accuracy of Doppler methods for clinical stroke volume determinations. Am Heart J 1990; 120: 116-123.
21. Freedman DS, Williamson DF, Gunter EW, Byers T: Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141: 637-644.
22. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH: Effect of growth on variability of left ventricular mass: assessment of allometric signals in adult and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25: 1056-1062.
23. Levy D, Savage DD, Garrison RJ, Anderson D, Kannel WB, Castelli WP: Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1997; 59: 956-960.
24. Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
25. Fang J, Alderman MH: Serum uric acid and cardiovascular motality: the NHANES I Epidemiologic Follow-up Study, 1971-1992. JAMA 2000; 283: 2404-2410.
26. Gerstenblith G, Frederiksen J, Yin FC, Fortuin NJ, Lakatta EG, Weisfeldt ML: Echocardiographic assessment of a normal adult aging population. Circulation 1977; 56: 273-278.
27. Pearson AC, Gudipati CV, Labovitz AJ: Effects of aging on left ventricular structure and function. Am Heart J 1991; 121: 871-875.
28. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG: Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817-821.
29. Grundy SM: Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997; 95: 1-4.
30. Ward HJ: Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998; 352: 670-671.
31. Johnson RJ, Kang D-H, Feig D, et al: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190.
32. Facchini F, Chen Y-DI, Hollenbeck CB, Reaven GM: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-3011.
33. Iwashima Y, Horio T, Kuroda S, et al: Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. Hypertens Res 2002; 25: 49-56.
34. Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G: When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J 1999; 340: 143-152.
35. Furumoto T, Saito N, Dong J, et al: Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients: Implications for early atherosclerosis. Hypertens Res 2002; 25: 475-480.
36. Verdecchia P, Reboldi G, Schillaci G, et al: Circulating insulin and insulin-like growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999; 100: 1802-1807.
37. Butler R, Morris AD, Belch JJF, Hill A, Struthers AD: Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746-751.
38. Høieggen A, Alderman MH, Kjeldsen SE, et al: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049.